Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGM2 | P21980 | 12/20 | 0.73 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | ITGB3 | P05106 | 7/20 | 0.45 |
| ▸ | ITGAV | P06756 | 7/20 | 0.45 |
| ▸ | ITGA2B | P08514 | 4/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1091637 | 1.00 | TGM2 (0.73) | TGM2CYP1A2ITGB3ITGAVITGA2B | |
| SCHEMBL1091635 | 1.00 | TGM2 (0.73) | TGM2CYP1A2ITGB3ITGAVITGA2B | |
| SCHEMBL1092076 | 0.89 | TGM2 (0.67) | TGM2CYP1A2ITGB3ITGAVITGA2B | |
| SCHEMBL1092077 | 0.89 | TGM2 (0.67) | TGM2CYP1A2ITGB3ITGAVITGA2B | |
| SCHEMBL1091157 | 0.88 | TGM2 (0.93) | TGM2 | |
| SCHEMBL1091124 | 0.88 | TGM2 (0.93) | TGM2 | |
| SCHEMBL1091121 | 0.88 | TGM2 (0.93) | TGM2 | |
| SCHEMBL3015992 | 0.88 | TGM2 (0.93) | TGM2 | |
| SCHEMBL1091158 | 0.88 | TGM2 (0.93) | TGM2 | |
| SCHEMBL9826332 | 0.87 | TGM2 (0.75) | TGM2CYP1A2ITGB3ITGAVITGA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8871718-B2 | Transglutaminase inhibitors and methods of use thereof | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2014-10-28 | — | — | US | disclosed |
| US-8871718-B2 | Transglutaminase inhibitors and methods of use thereof | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2014-10-28 | — | — | US | disclosed |
| US-20130102633-A1 | TRANSGLUTAMINASE INHIBITORS AND METHODS OF USE THEREOF | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2013-04-25 | — | — | US | disclosed |
| US-20130102633-A1 | TRANSGLUTAMINASE INHIBITORS AND METHODS OF USE THEREOF | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2013-04-25 | — | — | US | disclosed |
| US-7265093-B2 | Drug therapy for Celiac Sprue | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2007-09-04 | — | — | US | disclosed |
| US-20040167069-A1 | Drug therapy for Celiac Sprue | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2004-08-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130102633-A1 | TRANSGLUTAMINASE INHIBITORS AND METHODS OF USE THEREOF | TGM2, TGM3, TGM1 | TGM2 1/4885CYP1A2 1958/4885ITGB3 1426/4885 |
| US-20040167069-A1 | Drug therapy for Celiac Sprue | SI, DNPEP, SPINT2 | TGM2 13/4885CYP1A2 2474/4885ITGB3 3613/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.